AbbVie, Bristol-Myers Squibb, Eli Lilly, and AstraZeneca participated in drug delivery innovation discussions and partnerships.

The entities involved

• AbbVie →

  pharmaceutical company

  • MarketBeat's screener has identified a list of dividend stocks.Sun 22:22
  • AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.Sun 13:48
• Bristol-Myers Squibb →

  American pharmaceutical company

  • Bristol-Myers Squibb is developing innovative treatments and supporting Cyprus' national effort in haematology.Mon 13:45
  • FDA gave tentative approval to Lupin for an alternative formulation of a Bristol-Myers Squibb drug, which Lupin plans to manufacture in Somerset.Mon 09:09
• Eli Lilly and Company →

  American pharmaceutical company

  • ExxonMobil, Berkshire Hathaway, and Eli Lilly are top holdings in the Avantis ETF.Mon 17:18
  • The FDA approved Olumiant for pediatric indications on September 1, 2026.Mon 05:59

Related events

• Cocrystal Pharma and Bristol-Myers Squibb are competing for investment as healthcare companies.Sun 22:20
• Bristol-Myers Squibb and Pfizer are co-marketing Eliquis, while both companies are noted as dividend payers.Aug 25
• Bristol-Myers Squibb and Johnson & Johnson are both companies that are currently targets of LB Pharmaceuticals.Sep 9
• Bristol-Myers Squibb has taken ownership of Celgene's drug.Jun 7
• Bristol-Myers Squibb and AstraZeneca announced a collaboration on advanced cancer drug development.Aug 18